Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$11.37 -0.5%	$8.70	$5.29 ▼ $11.80	$1.50B	1.23	2.57 million shs	2.50 million shs
MRUS Merus	$64.00 +1.0%	$58.10	$33.19 ▼ $67.59	$4.84B	1.09	697,490 shs	557,225 shs
PCVX Vaxcyte	$29.90 -0.4%	$34.43	$27.66 ▼ $121.06	$3.88B	1.21	1.19 million shs	1.96 million shs
TLX Telix Pharmaceuticals	$11.34 -3.7%	$15.59	$11.34 ▼ $30.36	$3.84B	N/A	64,757 shs	155,231 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	0.00%	+8.39%	+27.32%	+42.13%	+113.72%
MRUS Merus	0.00%	-2.38%	+16.13%	+54.89%	+30.61%
PCVX Vaxcyte	0.00%	-9.45%	-17.49%	-4.04%	-57.60%
TLX Telix Pharmaceuticals	0.00%	-13.10%	-29.57%	-33.99%	+1,133,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	2.5041 of 5 stars	1.5	1.0	0.0	0.0	4.0	2.5	3.1
MRUS Merus	3.0124 of 5 stars	3.5	4.0	0.0	0.0	2.9	2.5	0.0
PCVX Vaxcyte	2.0289 of 5 stars	3.5	2.0	0.0	0.0	2.4	1.7	0.0
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$12.00	5.54% Upside
MRUS Merus	3.09	Buy	$88.50	38.28% Upside
PCVX Vaxcyte	3.09	Buy	$136.50	356.52% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.33	96.94% Upside

Current Analyst Ratings Breakdown

Latest AUPH, TLX, PCVX, and MRUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	PCVX Vaxcyte	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/6/2025	MRUS Merus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$97.00 ➝ $96.00
8/1/2025	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $9.00
7/30/2025	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00
7/9/2025	TLX Telix Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/3/2025	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
6/12/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00
6/5/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	6.37	$0.31 per share	36.87	$2.55 per share	4.46
MRUS Merus	$56.23M	86.09	N/A	N/A	$11.13 per share	5.75
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A
TLX Telix Pharmaceuticals	$516.72M	7.43	$0.11 per share	99.31	$1.12 per share	10.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.43	26.44	20.30	N/A	23.31%	20.06%	13.81%	N/A
MRUS Merus	-$215.33M	-$5.50	N/A	N/A	N/A	-685.64%	-50.28%	-42.00%	N/A
PCVX Vaxcyte	-$463.93M	-$3.99	N/A	N/A	N/A	N/A	-16.55%	-15.72%	N/A
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	23.63	N/A	N/A	N/A	N/A	8/20/2025 (Estimated)

Latest AUPH, TLX, PCVX, and MRUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	H1 2025	TLX Telix Pharmaceuticals	$0.2160	N/A	N/A	N/A	$316.69 million	N/A
8/6/2025	Q2 2025	PCVX Vaxcyte	-$1.12	-$1.22	-$0.10	-$1.22	N/A	N/A
8/5/2025	Q1 2025	MRUS Merus	-$1.17	-$2.23	-$1.06	-$2.23	$9.77 million	$8.83 million
7/31/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.17	$0.16	-$0.01	$0.16	$64.27 million	$70.01 million
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.18	5.23	4.63
MRUS Merus	N/A	8.39	5.86
PCVX Vaxcyte	N/A	17.70	17.70
TLX Telix Pharmaceuticals	0.99	2.78	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
MRUS Merus	96.14%
PCVX Vaxcyte	96.78%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
MRUS Merus	4.57%
PCVX Vaxcyte	3.10%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	131.63 million	115.57 million	Optionable
MRUS Merus	37	75.63 million	72.18 million	Optionable
PCVX Vaxcyte	160	129.82 million	125.80 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.40 million	N/A	N/A

AUPH, TLX, PCVX, and MRUS Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsÂ On Behalf of Investors of Telix Pharmaceuticals Limited â€“ TLX

August 9 at 12:05 PM | globenewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

August 8 at 3:58 PM | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?

August 7 at 2:46 PM | marketbeat.com

ABC Arbitrage SA Takes Position in Telix Pharmaceuticals Limited (NASDAQ:TLX)

August 7 at 7:33 AM | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's Why

August 6, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

August 6, 2025 | prnewswire.com

Broker says Telix shares could surge 80% higher after selloff

August 5, 2025 | msn.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

August 5, 2025 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 52-Week Low - Should You Sell?

August 5, 2025 | marketbeat.com

TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm

July 31, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

July 31, 2025 | prnewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

July 31, 2025 | prnewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low - Should You Sell?

July 30, 2025 | marketbeat.com

Telix H1 2025 Results: Investor Webcast Notification

July 29, 2025 | globenewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

July 29, 2025 | globenewswire.com

Telix Pharmaceuticals: Assessing The Market's Pullback On SEC Inquiry

July 29, 2025 | seekingalpha.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX

July 28, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

July 27, 2025 | prnewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - What's Next?

July 25, 2025 | marketbeat.com

Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 24, 2025 | tmcnet.com

Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

July 24, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH, TLX, PCVX, and MRUS Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$11.37 -0.06 (-0.52%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$11.32 -0.04 (-0.40%)

As of 08/8/2025 07:57 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Merus NASDAQ:MRUS

$64.00 +0.61 (+0.96%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$63.98 -0.02 (-0.02%)

As of 08/8/2025 06:50 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Vaxcyte NASDAQ:PCVX

$29.90 -0.11 (-0.37%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$29.92 +0.02 (+0.05%)

As of 08/8/2025 07:29 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Telix Pharmaceuticals NASDAQ:TLX

$11.34 -0.44 (-3.74%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$11.38 +0.04 (+0.35%)

As of 08/8/2025 07:54 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time